Efficacy of N-acetylcysteine and all-trans retinoic acid in restoring in vitro effective hemopoiesis in myelodysplastic syndromesAgostino Cortelezzi, Anna Teresa Maiolo, Chiara Cattaneo et al.|Leukemia Research|2000Cited by 10
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or <i>TP53</i> MutationsJeff P. Sharman, Franck Morschhauser, Roberto Marasca et al.|Blood|2024Cited by 3
Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO TrialPaolo Sportoletti, Jeff P. Sharman, Luca Laurenti et al.|Blood|2024Cited by 0
Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trialHyun Yong Jin, Franck Morschhauser, Jeff P. Sharman et al.|Blood|2025Cited by 0